Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention of ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPN Preclinical data show ...

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and to induce PD-1 receptor internalization (endocytosis ...

In patients with bladder cancer, lactylation score may predict survival and efficacy of immune checkpoint inhibitor treatment, according to researchers.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Abstract Title: Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with ...

Novocure (NVCR) announced that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.

Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.

To prevent the third most lethal cancer in Spain from becoming the second by 2030, clinicians are seeking to increase the ...